Dolby Family Ventures invests in Alzheimer's research
Dolby Family Ventures has led a $5.5 million funding round in PharmatrophiX, focused on developing drugs for neurodegenerative and other disorders. Dolby invested $2 million into the funding round. The family office also invested $500,000 as part of a $1 million seed round in Cortexyme, which is developing therapeutic and diagnostics for Alzheimer's Disease and other disorders.
6 October 2014•3 mins read
